Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ear zap eases pancreatitis pain? new study says maybe.

NCT ID NCT06998784

Symptom relief Sponsor: Air Force Military Medical University, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a non-invasive device that stimulates a nerve in the ear (taVNS) to see if it can calm inflammation and improve gut function in people with acute pancreatitis. Sixty adults with early-stage pancreatitis received either the real stimulation or a sham device. The goal was to see if the treatment could reduce symptoms and speed up recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

May 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. AP patients aged 18-80 years. 2. PAN-PROMISE score ≥15 and no participation in any other clinical trials within the past 3 months. 3. AP patients who presented to the emergency department no more than 24 hours after symptom onset and who had received a diagnosis no more than 8 hours before enrollment. Exclusion Criteria: 1. Patients with an APACHE II score≥8, a C-reactive protein (CRP) level \> 150 mg/L, or organ failure at baseline (shock, respiratory failure, or renal failure) were excluded. 2. Presence of diseases or conditions different from AP that may interfere with the scale, for example, other causes of abdominal pain (especially acute cholecystitis), obstruction of the digestive tract (peptic pyloric stenosis, gastrointestinal anastomotic stenosis, diabetic gastroparesis, gastrointestinal neoplasia...), nausea-vomiting (brain tumour, chemotherapy...) or weakness (pre-existing anaemia with haemoglobin \<9 g/dL, heart failure or respiratory insufficiency associated with minimal effort dyspnoea, or domiciliary treatment with O2, advanced neoplasms or other debilitating diseases); 3. Implanted cardiac pacemaker or other electronic devices; 4. Prior treatment with transcutaneous auricular vagus nerve stimulation (taVNS); 5. Known malignancy; 6. Severe cardiovascular/cerebrovascular, hepatic, or renal diseases; 7. Cognitive impairment, psychiatric disorders, or other conditions that may affect patient cooperation; 8. Refusal to sign informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pancreatitis (AP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute pancreatitis pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pancreatitis (AP) Vagus nerve stimulations

Contacts and locations

Locations

  • Department of Gastroenterology , Tangdu Hospital , Fourth Military Medical University

    Xi'an, Shaanxi, 710038, China

  • Department of Gastroenterology, 986 Hospital of Xijing Hospital, Fourth Military Medical University

    Xi'an, Shaanxi, 710054, China

  • Shaanxi Second People's Hospital

    Xi'an, Shaanxi, 710000, China

  • The 980th Hospital of the PLA Joint Logistics Support Force (Primary Bethune International Peace Hospital of PLA)

    Shijiazhuang, Hebei, 050082, China

  • Xijing Hospital of Digestive Diseases

    Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.